Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice

Hepatology

Volumn 56, Issue 5, 2012, Pages 1924-1933

  Höchst, Bastian ^a   Schildberg, Frank A ^a   Böttcher, Jan ^a   Metzger, Christina ^a   Huss, Sebastian ^a,b   Türler, Andreas ^c   Overhaus, Markus ^c   Knoblich, Andreas ^d   Schneider, Berthold ^d   Pantelis, Dimitrios ^e   Kurts, Christian ^a   Kalff, Jörg C ^e   Knolle, Percy ^a   Diehl, Linda ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c Johanniter Krankenhaus   (Germany)

^d ST MARIEN HOSPITAL   (Germany)

^e UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD44V ANTIGEN; MANNOSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CD8+ T LYMPHOCYTE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; ENDOTHELIUM CELL; EX VIVO STUDY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; IN VIVO STUDY; LIVER SINUSOID; LYMPHOCYTE SUBPOPULATION; MEMORY T LYMPHOCYTE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD274; ANTIGENS, CD44; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; ENDOTHELIAL CELLS; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; L-SELECTIN; LEUKOCYTES, MONONUCLEAR; LIVER; LYMPHOCYTE COUNT; MICE; MICE, TRANSGENIC; PHENOTYPE;

EID: 84868201817     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25844     Document Type: Article

References (26)

1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570.
2. Garrido F, Algarra I. MHC antigens and tumor escape from immune surveillance. Adv Cancer Res 2001; 83: 117-158.
3. Tian M, Schiemann WP. The TGF-beta paradox in human cancer: an update. Future Oncol 2009; 5: 259-271.
4. Katz JB, Muller AJ, Prendergast GC. Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008; 222: 206-221.
5. Du C, Wang Y. The immunoregulatory mechanisms of carcinoma for its survival and development. J Exp Clin Cancer Res 2011; 30: 12.
6. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010; 127: 759-767.
7. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-4506.
8. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005; 23: 338-351.
9. Fan B, Xiong B. Investigation of serum tumor markers in the diagnosis of gastric cancer. Hepatogastroenterology 2011; 58: 239-245.
10. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010; 28: 2159-2166.
11. Erlandsson Harris H, Andersson U. Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 2004; 34: 1503-1512.
12. Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 1997; 186: 239-245.
13. von Oppen N, Schurich A, Hegenbarth S, Stabenow D, Tolba R, Weiskirchen R, et al. Systemic antigen cross-presented by liver sinusoidal endothelial cells induces liver-specific CD8 T-cell retention and tolerization. HEPATOLOGY 2009; 49: 1664-1672.
14. Limmer A, Ohl J, Kurts C, Ljunggren HG, Reiss Y, Groettrup M, et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat Med 2000; 6: 1348-1354.
15. Diehl L, Schurich A, Grochtmann R, Hegenbarth S, Chen L, Knolle PA. Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance. HEPATOLOGY 2008; 47: 296-305.
16. Stewart TJ, Smyth MJ. Improving cancer immunotherapy by targeting tumor-induced immune suppression. Cancer Metastasis Rev 2011; 30: 125-140.
17. Limmer A, Ohl J, Wingender G, Berg M, Jungerkes F, Schumak B, et al. Cross-presentation of oral antigens by liver sinusoidal endothelial cells leads to CD8 T cell tolerance. Eur J Immunol 2005; 35: 2970-2981.
18. Berg M, Wingender G, Djandji D, Hegenbarth S, Momburg F, Hammerling G, et al. Cross-presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-specific CD8+ T cell tolerance. Eur J Immunol 2006; 36: 2960-2970.
19. Burgdorf S, Kautz A, Bohnert V, Knolle PA, Kurts C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 2007; 316: 612-616.
20. Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 2010; 10: 753-766.
21. Donati M, Brancato G, Donati A. Clinical biomarkers in hepatocellular carcinoma (HCC). Front Biosci (Schol Ed) 2010; 2: 571-577.
22. Kim HJ, Yu MH, Kim H, Byun J, Lee C. Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep 2008; 41: 685-692.
23. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4: 225-234.
24. Raziorrouh B, Ulsenheimer A, Schraut W, Heeg M, Kurktschiev P, Zachoval R, et al. Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4(+) T cells in patients with chronic infection. Gastroenterology 2011; 141: 1422-1431.
25. Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Totterman TH. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 2010; 33: 225-235.
26. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-3175.